Maker of brand name anti-stroke drug makes ‘a business decision’ about the drug
A drug designed to cut down on the chances of strokes in people who have suffered strokes or mini-strokes won’t be on the U.S. market in brand name form after June 11.
Tuesday’s FDA drug shortage update said a “business decision” made by Boehringer Ingelheim Pharmaceuticals (BIPI) “will no longer be supplying the market with Aggrenox capsules after June 11, 2020.”
Aggrenox’s NDC registry states, “This medication is used to reduce the risk of stroke in patients who have had mini-strokes (transient ischemic attacks) or a previous stroke due to a blood clot and are at high risk for another stroke.”
The prescription drug comes in 25 mg/200 mg capsules. Aggrenox will remain available in generic form, often sold under the name “Aspirin And Dipyridamole.”
This story was originally published May 27, 2020 at 11:08 AM with the headline "Maker of brand name anti-stroke drug makes ‘a business decision’ about the drug."
